New chip to capture live tumour cells in blood

Image
Press Trust of India Beijing
Last Updated : Aug 09 2013 | 3:06 PM IST
Chinese scientists have developed a new microfluidic chip that can quickly and efficiently segregate and capture live circulating tumour cells (CTCs) from a patient's blood.
The new system captures more than 90 per cent of the CTCs, and can help advance cancer screening methods and treatment assessments.
Tumour cells circulating within a patient's bloodstream can carry cancer from a primary tumour site to distant sites of the body, spreading the disease.
Many currently available devices for detecting CTCs in patients' blood are either too slow for clinical use or have other problems, such as a reduced ability to distinguish between the rare CTCs and more common white blood cells and other non-tumour cells.
The chip can reduce overall processing time, thanks in part to a step in which red blood cells are selectively lysed, or broken apart.
Lysing the red blood cells diminishes the tendency of blood to clog the system, a common problem that slows processing time in similar CTC filtering devices.
The ability to count live, individual CTCs in the bloodstream can help doctors determine the severity of a cancer, since CTC density in the blood is linked to the progression of the disease and patients' likelihood of survival.
The new method could also improve "liquid biopsy" techniques, in which a small amount of blood is drawn as an alternative to conventional tissue biopsies of primary or metastatic tumours.
In addition to potentially improving screening tests, the team believes their approach may someday help doctors control CTC-induced metastasis, which the researchers said can be far more lethal than the original tumour.
"Because our chip is able to capture viable CTCs, it creates opportunities for the development of new and efficient cancer biomarkers," said co-author Ray Han, a professor at Peking University in Beijing.
It also gives researchers a chance to realise what Han called "the grandest dream of all: a technology capable of directly removing CTCs from the human bloodstream - a form of CTC dialysis."
The study was published in the journal Biomicrofluidics, which is produced by American Institute of Physics (AIP) Publishing.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 09 2013 | 3:06 PM IST

Next Story